2009
DOI: 10.15407/scin5.01.062
|View full text |Cite
|
Sign up to set email alerts
|

Application of Cancer Vaccines of IEPOR Series into Clinical Practice of Oncological Establishments of Ukraine

Abstract: Наведено огляд результатів клінічних досліджень ефективності протипухлинних вакцин, створених на основі препаратів аутологічних чи алогенних пухлинних клітин або їхніх лізатів. Наведені основні результати клінічних досліджень розроблених в Інституті експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України протипухлинних вакцин, виготовлених з аутологічних пухлинних клітин за допомогою продуктів синтезу B. subtilis. К л ю ч о в і с л о в а: протипухлинні вакцини, імунотерапія раку,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 53 publications
0
2
0
Order By: Relevance
“…The rat embryo nervous tissue vaccine ('xeno rat' vaccine) used in the present study has been patented by the Ukrainian Intellectual Property Institute (27). The vaccine contains a protein fraction of nervous tissue from late gestation stage rat embryo (a source of TAAs) and an adjuvant, which is a protein-containing metabolite of B. subtilis В-7025 (molecular weight, 70 kDa) (27).…”
Section: Mice and Cell Linesmentioning
confidence: 99%
See 1 more Smart Citation
“…The rat embryo nervous tissue vaccine ('xeno rat' vaccine) used in the present study has been patented by the Ukrainian Intellectual Property Institute (27). The vaccine contains a protein fraction of nervous tissue from late gestation stage rat embryo (a source of TAAs) and an adjuvant, which is a protein-containing metabolite of B. subtilis В-7025 (molecular weight, 70 kDa) (27).…”
Section: Mice and Cell Linesmentioning
confidence: 99%
“…The rat embryo nervous tissue vaccine ('xeno rat' vaccine) used in the present study has been patented by the Ukrainian Intellectual Property Institute (27). The vaccine contains a protein fraction of nervous tissue from late gestation stage rat embryo (a source of TAAs) and an adjuvant, which is a protein-containing metabolite of B. subtilis В-7025 (molecular weight, 70 kDa) (27). The whole chicken embryo vaccine was prepared as follows: 7-day-old chicken embryos were rinsed twice briefly in cold 0.9% NaCl solution, homogenized and then extracted with 0.9% NaCl solution containing 0.1% EDTA for 60 min at 4˚C by agitation.…”
Section: Mice and Cell Linesmentioning
confidence: 99%